PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Benzopyrans”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1979

Nabilone: a pressure-reducing synthetic benzopyran in open-angle glaucoma.

Nabilone is a synthesized crystalline benzopyran that resembles the cannabinols but is not a tetrahydrocannabinol. Oral administration of 0.5 to 2 mg to patients with open-angle glaucoma reduced the intraocular pressure from 10% to 54% with an average of 28%. Administration of a topical ophthalmic nabilone solution (0.1 mg/drop) to both eyes of adult albino rabbits (1.5 to 3.5 kg) lowered the IOP an average of 25%. The peak action of the nabilone administered in this manner was 60 minutes, with a return to normal IOP by 180 minutes. Tolerance developed in rabbits after one week of topical administration.

Administration, Oral↗
PubMed1978

Structure-activity correlations for a series of antiallergy agents. Oxanilic, quinaldic, and benzopyran-2-carboxylic acids.

Ab initio Hartree-Fock SCF calculations with the molecular fragment technique have been performed on several drugs which exhibit activity in the rat passive cutaneous anaphylaxis (PCA) assay. Representative molecules of the following types were included in the series: oxanilic acids, 1,4-dihydro-4-oxoquinaldic acids, and 4-oxo-4H-1-benzopyran-2-carboxylic acids. A quantitative relationship has been established between the observed biological activity and an electronic index obtained from the calculations. The correlation is rationalized in terms of charge-transfer stabilization of the drug-receptor complex.

Amino Acids↗
PubMed1978

Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.

The synthesis and properties of the title compounds 1 are described. Several of these compounds, in addition to being potent inhibitors of the passive cutaneous anaphylaxis reaction of rats against egg albumin challenge, significantly block the effects of several mediators of anaphylaxis in isolated smooth muscle preparations. An improved procedure for the isolation and partial purification of SRS-A from chopped guinea pig lung tissue is also described.

Anaphylaxis↗
PubMed1977

Synthesis and structure-activity relationships of 5H,11 H-[I]benzopyrano[4,3-g]benzopyran-9-carboxylic acids.

The synthesis and properties of the title compounds 1 are described. Many of these compounds are potent inhibitors of the passive cutaneous anaphylaxis reaction of rats against egg albumin challenge. Structural variations include substitutions in the 2, 3, 4, 5, 7, and 12 position of the nucleus 1. A novel rearrangement from a compound of the related [3,4-f] series to this group is reported.

Animals↗
PubMed1975

In vitro antagonism of the mediators of allergy by a benzopyrano-benzopyran carboxylic acid PR-D-92-EA.

PR-D-92-EA was tested on isolated guinea pig ileum and rat stomach strips for activity against mediators probably released after allergen antibody union. It antagonized the response produced by histamine, bradykinin, serotonin, prostaglandin E2, prostaglandin F2ALPHA and slow-reacting substance of anaphylaxis (SRS-A). The concentrations which blocked 50% of the response were 150, 145, 92, 70, 47, and 32 mug/ml, respectively. This compound may be useful in the treatment of allergic conditions.

Animals↗
PubMedDate not supplied

A review of the literature of rotenone, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-1-benzopyrano[3,5-b]furo[2,3-h][1]benzopyran-6(6h)-one.

The chemistry, biotransformation, pharmacology, toxicology, and carcinogenicity of rotenone have been reviewed. Further investigation of the biotransformation pathways of rotenone and other rotenoids should be undertaken. The acute and chronic toxicology, particularly at low concentration, should be determined in order to develop toxicity rating for this class of chemicals. A mutagenic study utilizing all presently available methods would add further knowledge concerning sites of action. More information is required to properly evaluate the hazards to humans from rotenone and other rotenoids. Carcinogenic studies at low concentrations with large groups of rodents must be undertaken to settle the present dilemma of carcinogenicity vs. non-carcinogenicity. Moreover, an epidemiological study of exposed workers might develop information concerning the toxicology of rotenone as well as its possible carcinogenicity to humans.

Animals↗
PubMed1978

A new warfarin metabolite: structure and function.

The metabolism of the clinically utilized, anticoagulant warfarin [4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one] by rat liver microsomes has been investigated. The structure of a new warfarin metabolite [4-hydroxy-3-(3-oxo-1-phenyl-1-butenyl)-2H-1-benzopyran-2-one] (dehydrowarfarin) has been determined by mass spectral comparison with the chemically synthesized compound. The formation of dehydrowarfarin is catalyzed by cytochrome P-450 and is unusual in that the final product is effectively dehydrogenated warfarin.

Animals↗
PubMed1977

Microbiological degradation of bile acids. Metabolites formed from 3-(3a alpha-hexahydro-7a beta-methyl-1,5-dioxoindan-4 alpha-yl) propionic acid by Streptomyces rubescens.

1. The metabolism of 3-(3a alpha-hexahydro-7a beta-methyl-1,5-dioxoindan-4 alpha-yl)propionic acid (III), which is a possible precursor of 2,3,4,6,6a beta, 7,8,9,9a alpha,9b beta-decahydro-6a beta-methyl-1H-cyclopenta[f]quinoline-3,7-dione (II) formed from cholic acid (I) by streptomyces rubescens, was investigated by using the same organism. 2. This organism effected amide bond formation, reduction of the carbonyl groups, trans alpha beta-desaturation and R-oriented beta-hydroxylation of the propionic acid side chain and skeleton cleavage, and the following metabolites were isolated as these forms or their derivatives: compound (II), 1,2,3,4 a beta,-5,6,6a beta,7,8,9a alpha,9b beta-dodecahydro-6a beta -methylcyclopental[f][1]benzopyran-3,7-dione (IVa), (1R)-1,2,3,4a beta,5,6,6a beta,7,8,9.9a alpha,9b beta-dodecahydro-1-hydroxy-6a beta-methylcyclopenta[f][1]benzopyran-3,7-dione (IVb), (E)-3-(3aalpha-hexahydro-5 alpha-hydroxy-7a beta-methyl-l-oxo-indan-4 alpha-yl)prop-2-enoic acid (V), (+)-(5R)-5-methyl-4-oxo-octane-1,8-dioic acid (VI), 3-(4-hydroxy-5-methyl-2-oxo-2H-pyran-6-yl)propionic acid (VII) and 3-(3a alpha-hexahydro-1 beta-hydroxy-7a beta-methyl-5-oxoindan-4 alpha-yl)propionic acid (VIII). The metabolites (IVb), (V), (VI) and (VII) were new compounds, and their structures were established by chemical synthesis. 3. The question of whether these metabolites are true degradative intermediates is discussed, and a degradative pathway of compound (III) to the possible precursor of compound (VII), 7-carboxy-4-methyl-3,5-dioxoheptanoyl-CoA (IX), is tentatively proposed. The further degradation of compound (IX) to small fragments is also considered.

Bile Acids and Salts↗
PubMedDate not supplied

The metabolism of 14C-methoxsalen by the dog.

Single doses of 14C-methoxsalen (5 mg/kg) were administered iv to three dogs. Almost as much administered radioactivity was excreted in the feces as in the urine, suggesting that biliary secretion of metabolites was an important route of excretion. 14C-Methoxsalen disappeared rapidly from plasma, although plasma levels of radioactivity persisted for 5 weeks after drug administration. Evidence was obtained which suggested that the persistent plasma radioactivity was due to a metabolite bound to plasma protein. Four urinary metabolites were isolated. Three of the metabolites resulted from opening of the furan ring; these are 7-hydroxy-8-methoxy-2-oxo-2H-1-benzopyran-6-acetic acid (A), alpha,7-dihydroxy-8-methoxy-2-oxo-2H-1-benzopyran-6-acetic acid (B), and an unknown conjugate of A at the 7-hydroxy position. The fourth metabolite, formed by opening of the pyrone ring, is an unknown conjugate of (Z)-3-(6-hydroxy-7-methoxybenzofuran-5-yl)-2-propenoic acid.

Animals↗
PubMed1977

Pharmacologic profile of a new antiallergic compound PRD-92-Ea.

PRD-92-Ea [5,5-Dimethyl-11-oxo-5H, 11H-(2) benzopyrano (4,3-g) (1) benzopyran-9-carboxylic acid ethanolamine], was an active antiallergic compound in rat and monkey experimental models of immediate hypersensitivity. It inhibited, in a dose-dependent manner, the rat PCA reaction after both intravenous and oral administration. It also inhibited the degranulation of rat peritoneal mast cells after antigenic challenge. PRD-92-Ea was also active in preventing bronchoconstriction in Ascaris-sensitive Rhesus monkeys after intravenous, topical and oral administration. Using chopped monkey tissues, it was found that PRD-92-Ea prevented histamine release from the respiratory mast cells, but not from the cutaneous mast cells. No reason for this dichotomy of effect is known. PRD-92-Ea showed antagonistic activity against the allergic mediators released from mast cells. In order of decreasing potency it was active against SRS-A (monkey lung), PGF2alpha, PGE2, serotonin, bradykinin and histamine. Apart from its antiallergic effects PRD-92-Ea had no other significant pharmacological activity.

Animals↗
PubMed1976

Photocontrol of urease activity in spiropyran collagen membrane.

1. Collagen fibrils were modified with beta-1-[3,3-dimethyl-6'-nitrospiro-(indoline-2,2'-2H-benzopyran)] propionic anhydride. 2. Urease (urea amidohydrolase, EC 3.5.1.5) was immobilized in spiropyran collagen membrane. The activity of the urease-spiropyran collagen membrane was found to increase in the dark and then decrease with visible light irradiation. 3. The optimum pH of the urease-spiropyran collagen membrane under visible light was lowered in the dark. 4. The apparent Michaelis constant (K'm) of the urease-spiropyran collagen membrane in the dark was almost the same as that under visible light. The apparent maximum velocity was increased in the dark. 5. The diffusion coefficient of urea through the spiropyran collagen membrane in the dark was 1.4 times that under visible light. However, the increase of the diffusion rate was not responsible for the activity increase of the urease-spiropyran collagen membrane.

Collagen↗
PubMed1978

Benzopyrones. 14. Synthesis and antiallergic properties of some N-tetrazolylcarboxamides and related compounds.

A series of chromones containing an acidic group has been synthesized and screened for the ability to inhibit passive cutaneous anaphylaxis and the release of histamine from mast cells of the rat. Many of the chromones contain the N-(5-tetrazolyl)carboxamido group, a novel source of acidity. Others contain a carboxyl, C-(5-tetrazolyl), 5-(4H)-oxotetrazolinyl, or N-(5-tetrazolyl)sulfonamido function. The compounds were compared with cromolyn sodium (sodium cromoglycate) and many were found to be powerful inhibitors of anaphylaxis. The most potent was 7-methoxy-4-oxo-N-(5-tetrazolyl)-4H-1-benzopyran-2-carboxamide (15). Structure-activity relationships among the chromones and also some related compounds are discussed.

Anaphylaxis↗
PubMed1977

Antagonists of slow reacting substance of anaphylaxis. Synthesis of a series of chromone-2-carboxylic acids.

A series of substituted chromone-2-carboxylic acids was synthesized and tested as antagonists of SRS-A induced contractions of isolated guinea pig ileum. This work led to the discovery of sodium 7-[3-(4-acetyl-3hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylate (FPL 55712) which is the first reported specific antagonist of SRS-A. Some structural requirements for biological activity within this series are discussed.

Animals↗